DVAXライブシグナル | Getagraph.comで利益を最大化

売る 108130 min ago

@ $12.42

発行日: 14 2月 2024 @ 23:30

リターン: -8.57%

前回のシグナル: 2月 13 - 05:56

前回のシグナル: 買う

リターン: -2.97 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:40):

Stats
本日の出来高	209 465
平均出来高	1.96M
時価総額	1.48B
EPS	$0 ( 2024-02-22 )
次の収益日	( $-0.0500 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-227.10
ATR14	$0.00600 (0.05%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-29	Slebir John L	Sell	0	Common Stock
2024-03-29	Slebir John L	Sell	300 000	Stock Option (Right to Buy)
2024-03-29	Slebir John L	Sell	80 000	Stock Options (Right to Buy)
2024-03-29	Slebir John L	Sell	50 000	Restricted Stock Unit
2024-03-29	Slebir John L	Sell	88 000	Stock Options (Right to Buy)

INSIDER POWER
-33.88
Last 100 transactions
Buy: 1 153 769 \| Sell: 2 721 592

ボリューム相関

長: 0.10 (neutral)

短: -0.06 (neutral)

Signal:(76.401) Neutral

Dynavax Technologies Corp 相関

10 最も正の相関
RMRM	0.942
SUSL	0.937
FNILX	0.937
PABU	0.935
MOR	0.934
CATH	0.933
BUFF	0.932
CACG	0.932
VONE	0.929
USXF	0.927

10 最も負の相関
SDVY	-0.926
VC	-0.925
SMH	-0.923
OSIS	-0.923
HLNE	-0.922
NYMTM	-0.92
PSCI	-0.919
RNSC	-0.919
RNMC	-0.918
TER	-0.917

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Dynavax Technologies Corp 相関 - 通貨/商品

-0.17
( neutral )

0.03
( neutral )

0.00
( neutral )

-0.14
( neutral )

0.00
( neutral )

0.04
( neutral )

Dynavax Technologies Corp 財務諸表

Annual	2023
収益:	$232.28M
総利益:	$182.12M (78.40 %)
EPS:	$-0.0496

FY	2023
収益:	$232.28M
総利益:	$182.12M (78.40 %)
EPS:	$-0.0496

FY	2022
収益:	$722.68M
総利益:	$460.53M (63.73 %)
EPS:	$2.32

FY	2021
収益:	$439.44M
総利益:	$265.87M (60.50 %)
EPS:	$0.620

Financial Reports:

No articles found.

Dynavax Technologies Corp

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.